Clinical Trial

A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano [VPH]")

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates the long term protection provided by either one or two doses of the HPV vaccine for patients who were part of the ESCUDDO study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-15.
Trial Details
NCT Number NCT07706673
Lead Sponsor National Cancer Institute (NCI)
Collaborators: Merck Sharp and Dohme LLC
Conditions Human Papillomavirus-Related Malignant Neoplasm
Enrollment 9,700 participants
Start Date 2026-08-03
Primary Completion 2030-10-01 (estimated)
Study Completion 2031-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-28